Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts

Vincenzo Oliva, Giuseppe Fanelli, Siegfried Kasper, Joseph Zohar, Daniel Souery, Stuart Montgomery, Diego Albani, Gianluigi Forloni, Panagiotis Ferentinos, Dan Rujescu, Julien Mendlewicz, Martien J. Kas, Diana de Ronchi, Chiara Fabbri, Alessandro Serretti*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Social withdrawal is an early manifestation of several neuropsychiatric disorders, and it is characterised by a gradual disengagement from social interactions, potentially leading to complete isolation. This study investigated the association between social withdrawal at baseline and short-term symptom remission in five independent cohorts, including patients with major depressive disorder (MDD), bipolar spectrum disorders, and schizophrenia. Measures of social withdrawal were derived in each study, and clinical remission was estimated based on the psychopathological severity assessed after short-term psychopharmacological treatment (12weeks). Logistic regression was performed in each sample, adjusting for age and baseline psychopathological severity residualised for social withdrawal. Results were then meta-analysed across samples within a random-effect framework. A total of 4461 patients were included in the analyses (3195 patients with MDD, 655 with bipolar spectrum disorders and 611 with schizophrenia). The meta-analysis showed that higher baseline levels of social withdrawal were associated with a decreased likelihood of short-term remission (ORadj=0.67, 95% CI, 0.58-0.79, P=5.28×10−7), with the strongest effect in patients with schizophrenia. Overall, our study highlighted the need to address social withdrawal in the early phases of the disease to promote symptom remission in patients with major psychiatric disorders. Understanding the neurobiology underlying social withdrawal may aid the development of medications that can specifically reverse social impairment, thereby fostering clinical remission.

Original languageEnglish
Pages (from-to)38-45
Number of pages8
JournalInternational Clinical Psychopharmacology
Volume37
Issue number2
DOIs
StatePublished - 1 Mar 2022

Funding

FundersFunder number
European Federation of Pharmaceutical Industries and Associations
European Commission
Novartis
Innovative Medicines Initiative
CO-MED
Fondazione Umberto Veronesi
NIH-supported STARN01MH90003, N01MH8001
National Institute of Mental HealthN01MH090003, N01MH090001
CATIEN01MH900001
Horizon 2020 Framework Programme115916

    Keywords

    • Bipolar disorder
    • Major depressive disorder
    • Psychopharmacology
    • Remission
    • Schizophrenia
    • Social withdrawal
    • Transdiagnostic

    Fingerprint

    Dive into the research topics of 'Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts'. Together they form a unique fingerprint.

    Cite this